Kiora Pharmaceuticals (KPRX) Competitors $3.42 +0.19 (+5.88%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends KPRX vs. TTPH, VRCA, VYNE, RLYB, CVM, ANEB, CLNN, CERO, LVTX, and OSTXShould you be buying Kiora Pharmaceuticals stock or one of its competitors? The main competitors of Kiora Pharmaceuticals include Tetraphase Pharmaceuticals (TTPH), Verrica Pharmaceuticals (VRCA), VYNE Therapeutics (VYNE), Rallybio (RLYB), CEL-SCI (CVM), Anebulo Pharmaceuticals (ANEB), Clene (CLNN), CERo Therapeutics (CERO), LAVA Therapeutics (LVTX), and OS Therapies (OSTX). These companies are all part of the "medical" sector. Kiora Pharmaceuticals vs. Tetraphase Pharmaceuticals Verrica Pharmaceuticals VYNE Therapeutics Rallybio CEL-SCI Anebulo Pharmaceuticals Clene CERo Therapeutics LAVA Therapeutics OS Therapies Kiora Pharmaceuticals (NASDAQ:KPRX) and Tetraphase Pharmaceuticals (NASDAQ:TTPH) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, community ranking, earnings, profitability, institutional ownership, dividends and risk. Does the media refer more to KPRX or TTPH? In the previous week, Kiora Pharmaceuticals had 5 more articles in the media than Tetraphase Pharmaceuticals. MarketBeat recorded 5 mentions for Kiora Pharmaceuticals and 0 mentions for Tetraphase Pharmaceuticals. Tetraphase Pharmaceuticals' average media sentiment score of 0.00 beat Kiora Pharmaceuticals' score of -0.44 indicating that Tetraphase Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Kiora Pharmaceuticals Neutral Tetraphase Pharmaceuticals Neutral Which has higher earnings and valuation, KPRX or TTPH? Kiora Pharmaceuticals has higher revenue and earnings than Tetraphase Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKiora Pharmaceuticals$16M0.64-$12.51MN/AN/ATetraphase Pharmaceuticals$7.38M2.17-$70.08M-$22.85-0.10 Is KPRX or TTPH more profitable? Kiora Pharmaceuticals has a net margin of 0.00% compared to Tetraphase Pharmaceuticals' net margin of -798.18%. Kiora Pharmaceuticals' return on equity of 21.32% beat Tetraphase Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Kiora PharmaceuticalsN/A 21.32% 16.39% Tetraphase Pharmaceuticals -798.18%-210.86%-121.73% Which has more risk and volatility, KPRX or TTPH? Kiora Pharmaceuticals has a beta of -0.29, suggesting that its share price is 129% less volatile than the S&P 500. Comparatively, Tetraphase Pharmaceuticals has a beta of 2.33, suggesting that its share price is 133% more volatile than the S&P 500. Do insiders and institutionals believe in KPRX or TTPH? 77.0% of Kiora Pharmaceuticals shares are owned by institutional investors. Comparatively, 42.3% of Tetraphase Pharmaceuticals shares are owned by institutional investors. 1.5% of Kiora Pharmaceuticals shares are owned by company insiders. Comparatively, 5.7% of Tetraphase Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the MarketBeat Community prefer KPRX or TTPH? Tetraphase Pharmaceuticals received 367 more outperform votes than Kiora Pharmaceuticals when rated by MarketBeat users. However, 73.91% of users gave Kiora Pharmaceuticals an outperform vote while only 67.13% of users gave Tetraphase Pharmaceuticals an outperform vote. CompanyUnderperformOutperformKiora PharmaceuticalsOutperform Votes1773.91% Underperform Votes626.09% Tetraphase PharmaceuticalsOutperform Votes38467.13% Underperform Votes18832.87% Do analysts rate KPRX or TTPH? Kiora Pharmaceuticals currently has a consensus target price of $10.00, indicating a potential upside of 192.40%. Given Kiora Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Kiora Pharmaceuticals is more favorable than Tetraphase Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kiora Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Tetraphase Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryKiora Pharmaceuticals beats Tetraphase Pharmaceuticals on 12 of the 17 factors compared between the two stocks. Ad DTIDownload Our Tesla Ebook For FreeLike many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.To claim your copy free of charge simply follow this link. Get Kiora Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for KPRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KPRX vs. The Competition Export to ExcelMetricKiora PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.26M$6.45B$5.03B$8.81BDividend YieldN/A8.11%5.16%4.06%P/E RatioN/A10.78135.4117.82Price / Sales0.64243.751,160.9774.56Price / CashN/A22.1633.5332.53Price / Book0.485.474.674.68Net Income-$12.51M$153.61M$119.07M$226.08M7 Day Performance0.59%-2.00%-1.83%-1.04%1 Month Performance-2.01%-7.46%-3.60%1.04%1 Year Performance-32.14%31.82%31.66%26.28% Kiora Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KPRXKiora Pharmaceuticals2.9938 of 5 stars$3.42+5.9%$10.00+192.4%-32.4%$10.26M$16M0.0010TTPHTetraphase PharmaceuticalsN/A$2.20flatN/A+0.0%$15.98M$7.38M-0.10119VRCAVerrica Pharmaceuticals4.575 of 5 stars$0.89flat$9.60+981.8%-76.1%$40.58M$5.12M0.0040News CoverageVYNEVYNE Therapeutics2.55 of 5 stars$2.82+3.3%$6.88+143.8%-28.6%$40.27M$420,000.000.0030Analyst ForecastRLYBRallybio2.5309 of 5 stars$0.99+3.1%$9.75+880.8%-59.4%$39.85MN/A0.0040CVMCEL-SCIN/A$0.62-3.1%N/A-74.0%$39.75MN/A-1.0743Analyst DowngradeANEBAnebulo Pharmaceuticals2.5011 of 5 stars$1.52flat$8.00+426.3%-30.9%$39.42MN/A-5.074Analyst ForecastShort Interest ↓News CoverageGap UpCLNNClene3.1551 of 5 stars$4.09-12.2%$71.33+1,644.1%-56.6%$38.96M$650,000.000.00100Analyst RevisionHigh Trading VolumeCEROCERo TherapeuticsN/A$0.25-3.9%N/AN/A$38.79MN/A0.008Gap DownLVTXLAVA Therapeutics1.8053 of 5 stars$1.52-1.9%$6.00+294.7%+1.3%$38.53M$7.40M-1.6760OSTXOS TherapiesN/A$1.74-1.7%N/AN/A$37.59MN/A0.00N/AHigh Trading Volume Related Companies and Tools Related Companies Tetraphase Pharmaceuticals Competitors Verrica Pharmaceuticals Competitors VYNE Therapeutics Competitors Rallybio Competitors CEL-SCI Competitors Anebulo Pharmaceuticals Competitors Clene Competitors CERo Therapeutics Competitors LAVA Therapeutics Competitors OS Therapies Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:KPRX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kiora Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kiora Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KPRX Stock Alerts